Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rapid Micro Biosystems (RPID) Short-term Investments (2020 - 2025)

Rapid Micro Biosystems (RPID) has disclosed Short-term Investments for 6 consecutive years, with $18.3 million as the latest value for Q4 2025.

  • Quarterly Short-term Investments fell 45.99% to $18.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $18.3 million through Dec 2025, down 45.99% year-over-year, with the annual reading at $18.3 million for FY2025, 45.99% down from the prior year.
  • Short-term Investments hit $18.3 million in Q4 2025 for Rapid Micro Biosystems, down from $22.3 million in the prior quarter.
  • In the past five years, Short-term Investments ranged from a high of $94.4 million in Q2 2022 to a low of $1.2 million in Q1 2022.
  • Historically, Short-term Investments has averaged $42.5 million across 5 years, with a median of $33.8 million in 2024.
  • Biggest five-year swings in Short-term Investments: surged 7342.51% in 2022 and later tumbled 60.14% in 2025.
  • Year by year, Short-term Investments stood at $15.1 million in 2021, then surged by 439.93% to $81.6 million in 2022, then decreased by 16.93% to $67.8 million in 2023, then plummeted by 50.09% to $33.8 million in 2024, then crashed by 45.99% to $18.3 million in 2025.
  • Business Quant data shows Short-term Investments for RPID at $18.3 million in Q4 2025, $22.3 million in Q3 2025, and $12.9 million in Q2 2025.